Press Release – New York, NY – June 8, 2026 – Sichenzia Ross Ference Carmel LLP announced that it represented LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage pharmaceutical and med-tech company focused on new targets for cancer drug development and developing and commercializing cancer therapies, in its recently priced $16.6 million registered direct offering.
The SRFC team congratulates CEO Geordan Pursglove and the entire LIXTE Biotechnology team on the offering.
The SRFC team was led by partners Ross Carmel and Carl Kleidman, with associates Gary Eaton and Jacob Horowitz.